EpCAM (CD326) finding its role in cancer.
EpCAM (CD326) finding its role in cancer.
复制标题
DOI：
10.1038/sj.bjc.6603494
复制
发表时间：
2007-02-12
影响因子：
8.8
通讯作者：
中科院分区：
文献类型：
--
作者：
虽然上皮细胞粘附/激活分子（EpCAM/CD 326）是最早被鉴定的肿瘤相关抗原之一，但它从未像其他用于癌症治疗的靶蛋白那样受到同等程度的关注。同样令人惊讶的是，自从20世纪70年代末发现EpCAM以来，直到最近，EpCAM对致癌作用的实际贡献仍未被探索。随着第一届EpCAM生物学和临床应用国际研讨会的召开，这种情况正在改变。会议讨论的关键主题是EpCAM在各种癌症中的表达频率和水平及其预后潜力，EpCAM作为癌细胞致癌信号分子的作用，EpCAM导向免疫方法在临床开发中的最新进展以及EpCAM与其他蛋白质的相互作用，这可能为治疗窗口和抑制其在癌症中的促生长信号提供基础。EpCAM的未来研究可能会受益于统一的命名法，以及在过去30年中一直致力于这一癌症靶点的人员之间更频繁的交流，并将在未来这样做。
Although epithelial cell adhesion/activating molecule (EpCAM/CD326) is one of the first tumour-associated antigens identified, it has never received the same level of attention as other target proteins for therapy of cancer. It is also striking that ever since its discovery in the late 1970s the actual contribution of EpCAM to carcinogenesis remained unexplored until very recently. With a First International Symposium on EpCAM Biology and Clinical Application this is now changing. Key topics discussed at the meeting were the frequency and level of EpCAM expression on various cancers and its prognostic potential, the role of EpCAM as an oncogenic signalling molecule for cancer cells, recent progress on EpCAM-directed immunotherapeutic approaches in clinical development and the interaction of EpCAM with other proteins, which may provide a basis for a therapeutic window and repression of its growth-promoting signalling in carcinoma. Future research on EpCAM may benefit from a unified nomenclature and more frequent exchange among those who have been working on this cancer target during the past 30 years and will do so in the future.